Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investiga

tD33NAt

Active member
Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need...


YYEu8IBvhw8


More...
 
Top